FIELD: medicine.
SUBSTANCE: invention can find application in hematology clinics for correction of anemia in patients with beta-thalassemia dependent on erythrocyte transfusions. Preparation luspatercept in dose of 1.0–1.2 mg per kilogram of patient’s body weight is administered subcutaneously to the patients once every three weeks and additionally daily oral hydroxyurea in dose of 10–20 mg/kg and iron chelator deferasirox in dose of 10–40 mg/kg.
EFFECT: invention provides minimization or complete cancellation of red cell transfusions.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING THE PATIENTS SUFFERING FROM HEMOCHROMATOSIS WITH INJURED LIVER | 2000 |
|
RU2185832C2 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF ANEMIA OF CHRONIC DISEASES, IRON DEFICIENCY ANEMIA AND COMBINED VERSION OF ANEMIA OF CHRONIC DISEASES AND IRON DEFICIENCY ANEMIA IN CHRONIC HEPATITIS AND CIRRHOSIS OF LIVER | 2023 |
|
RU2817212C1 |
| METHOD FOR PREVENTING AND CORRECTING ANEMIA STATE IN METASTATIC MAMMARY GLAND CARCINOMA PATIENTS | 2005 |
|
RU2314122C2 |
| METHOD FOR EVALUATING EFFECTIVE IRON TRANSPORT IN PATIENT WITH RENAL INSUFFICIENCY | 2010 |
|
RU2436096C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF ANEMIA SYNDROME IN TYPE 1 AND TYPE 2 DIABETES MELLITUS | 2021 |
|
RU2770744C1 |
| METHOD OF PREOPERATIVE CORRECTION OF ANEMIA IN PATIENTS WITH COLORECTAL CANCER WITH LIVER METASTASES | 2023 |
|
RU2811959C1 |
| METHOD OF DIFFERENTIAL DIAGNOSTICS OF ANEMIA | 2017 |
|
RU2667471C1 |
| METHOD FOR IMPROVING QUALITY OF LIFE AND PROLONGING REMISSION PERIOD IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2014 |
|
RU2576837C1 |
| PHARMACEUTICAL COMBINED PREPARATIONS CONTAINING ERYTHROPOIETIN AND IRON PREPARATIONS | 1996 |
|
RU2173168C2 |
| METHOD OF TREATMENT OF ANEMIC SYNDROME IN CHILDREN ASSOCIATED WITH PERIORAL IMPACT OF MANGANESE AND CHLOROFORM FROM DRINKING WATER | 2017 |
|
RU2662148C1 |
